FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011517008> ?p ?o ?g. }

• W2011517008 endingPage "396" @default.
• W2011517008 startingPage "388" @default.
• W2011517008 abstract "Background The association between inhibition of tumour necrosis factor alpha (TNF-α) and new onset of neurological adverse events (AEs) is unclear. Aims To evaluate neurological AEs with TNF-α inhibitors reported to the Food and Drug Administration Adverse Event Reporting System (FAERS) utilising a standardised scoring tool for drug-induced AEs. Methods A search of FAERS for neurological AEs (January 1, 2000 to December 31, 2009) reported with infliximab, adalimumab, certolizumab and etanercept was performed. Full-text reports were accessed using the Freedom of Information Act and scored using Naranjo score, while accounting for temporal association, previous conclusive reports of the neurological AE with any TNF-α inhibitor, and alternate explanations including underlying disease, concomitant medications and comorbidities, such as diabetes mellitus. Results There were 772 reports. Most were in patients who had rheumatoid arthritis (393, 50.9%) followed by inflammatory bowel disease (140, 18.1%). No significant differences in age or gender were seen between IBD patients compared with rheumatological diseases (P = 0.584 and P = 0.055 respectively). Etanercept was reported most (327, 42.4%) followed by infliximab (276, 35.8%) (P = 0.008). Peripheral neuropathy was the most common neurological AE (296 reports, 38.3%) followed by central nervous system and/or spinal cord demyelination (153 reports, 19.8%). Majority (551, 71.4%) of the reports were of ‘possible’ AE with the remaining ‘probable’ AE and none identified as ‘definite’ AE. Conclusion While several neurological AEs have been described, definite association between de novo development of these AEs and exposure to TNF-α inhibitors was not established using the Naranjo score." @default.
• W2011517008 created "2016-06-24" @default.
• W2011517008 creator A5009302642 @default.
• W2011517008 creator A5052998816 @default.
• W2011517008 creator A5053690371 @default.
• W2011517008 creator A5054829171 @default.
• W2011517008 creator A5069136704 @default.
• W2011517008 date "2013-06-26" @default.
• W2011517008 modified "2023-10-07" @default.
• W2011517008 title "Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System" @default.
• W2011517008 cites W1580853286 @default.
• W2011517008 cites W1635237207 @default.
• W2011517008 cites W1964040898 @default.
• W2011517008 cites W1964162511 @default.
• W2011517008 cites W1979325825 @default.
• W2011517008 cites W1983808693 @default.
• W2011517008 cites W1999958699 @default.
• W2011517008 cites W2011395649 @default.
• W2011517008 cites W2019380311 @default.
• W2011517008 cites W202030915 @default.
• W2011517008 cites W2026229008 @default.
• W2011517008 cites W2033345378 @default.
• W2011517008 cites W2036346423 @default.
• W2011517008 cites W2045834553 @default.
• W2011517008 cites W2056014776 @default.
• W2011517008 cites W2066998519 @default.
• W2011517008 cites W2067978628 @default.
• W2011517008 cites W2074753508 @default.
• W2011517008 cites W2081098715 @default.
• W2011517008 cites W2081833623 @default.
• W2011517008 cites W2082197665 @default.
• W2011517008 cites W2092190921 @default.
• W2011517008 cites W2094671709 @default.
• W2011517008 cites W2105816635 @default.
• W2011517008 cites W2106353487 @default.
• W2011517008 cites W2112752031 @default.
• W2011517008 cites W2127131137 @default.
• W2011517008 cites W2138534069 @default.
• W2011517008 cites W2141046689 @default.
• W2011517008 cites W2153250998 @default.
• W2011517008 cites W2168014808 @default.
• W2011517008 cites W2177368405 @default.
• W2011517008 cites W2480036115 @default.
• W2011517008 cites W4241551895 @default.
• W2011517008 doi "https://doi.org/10.1111/apt.12385" @default.
• W2011517008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23802849" @default.
• W2011517008 hasPublicationYear "2013" @default.
• W2011517008 type Work @default.
• W2011517008 sameAs 2011517008 @default.
• W2011517008 citedByCount "75" @default.
• W2011517008 countsByYear W20115170082013 @default.
• W2011517008 countsByYear W20115170082014 @default.
• W2011517008 countsByYear W20115170082015 @default.
• W2011517008 countsByYear W20115170082016 @default.
• W2011517008 countsByYear W20115170082017 @default.
• W2011517008 countsByYear W20115170082018 @default.
• W2011517008 countsByYear W20115170082019 @default.
• W2011517008 countsByYear W20115170082020 @default.
• W2011517008 countsByYear W20115170082021 @default.
• W2011517008 countsByYear W20115170082022 @default.
• W2011517008 countsByYear W20115170082023 @default.
• W2011517008 crossrefType "journal-article" @default.
• W2011517008 hasAuthorship W2011517008A5009302642 @default.
• W2011517008 hasAuthorship W2011517008A5052998816 @default.
• W2011517008 hasAuthorship W2011517008A5053690371 @default.
• W2011517008 hasAuthorship W2011517008A5054829171 @default.
• W2011517008 hasAuthorship W2011517008A5069136704 @default.
• W2011517008 hasBestOaLocation W20115170081 @default.
• W2011517008 hasConcept C126322002 @default.
• W2011517008 hasConcept C134018914 @default.
• W2011517008 hasConcept C197934379 @default.
• W2011517008 hasConcept C2777105317 @default.
• W2011517008 hasConcept C2777138892 @default.
• W2011517008 hasConcept C2777226972 @default.
• W2011517008 hasConcept C2777575956 @default.
• W2011517008 hasConcept C2778260677 @default.
• W2011517008 hasConcept C2779134260 @default.
• W2011517008 hasConcept C2779384505 @default.
• W2011517008 hasConcept C2779901536 @default.
• W2011517008 hasConcept C2780132546 @default.
• W2011517008 hasConcept C555293320 @default.
• W2011517008 hasConcept C71924100 @default.
• W2011517008 hasConcept C90924648 @default.
• W2011517008 hasConceptScore W2011517008C126322002 @default.
• W2011517008 hasConceptScore W2011517008C134018914 @default.
• W2011517008 hasConceptScore W2011517008C197934379 @default.
• W2011517008 hasConceptScore W2011517008C2777105317 @default.
• W2011517008 hasConceptScore W2011517008C2777138892 @default.
• W2011517008 hasConceptScore W2011517008C2777226972 @default.
• W2011517008 hasConceptScore W2011517008C2777575956 @default.
• W2011517008 hasConceptScore W2011517008C2778260677 @default.
• W2011517008 hasConceptScore W2011517008C2779134260 @default.
• W2011517008 hasConceptScore W2011517008C2779384505 @default.
• W2011517008 hasConceptScore W2011517008C2779901536 @default.
• W2011517008 hasConceptScore W2011517008C2780132546 @default.
• W2011517008 hasConceptScore W2011517008C555293320 @default.
• W2011517008 hasConceptScore W2011517008C71924100 @default.
• W2011517008 hasConceptScore W2011517008C90924648 @default.

• next